Syndax Pharma: Continuing Execution In AML

2025-12-17 08:15:00 ET

Syndax Pharmaceuticals (NASDAQ: SNDX ) has transitioned to a commercial stage biopharma company with two FDA approved drugs: Revuforj and Niktimvo . Revuforj is a first-in-class menin inhibitor approved for the treatment of relapsed or refractory (R/R) acute myeloid leukemia (AML) targeting KMT2A-rearranged and NPM1-mutated subtypes. These subtypes occur in one out of three AML patients, a total population estimated at 6,500 patients per year in the US. Additionally, the company has moved this year to initiate Phase 3 clinical trials for front-line AML in KMT2A-r or NPM1-m patients, potentially treating 9,000 patients a year for a total addressable market (TAM) of $5B+ among 15,500 patients....

Read the full article on Seeking Alpha

For further details see: